Skip to main content

Madrigal Pharmaceuticals, Inc.

MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001157601

In the last 90 days, Madrigal Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 3 sales; 414 institutions reported holding it in 13F filings for Q2 2026, worth $12.7B in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $7.95M in total
3
13F holdersQ2 2026, +38 vs. previous quarter
414
13F valueReported value at the end of Q2 2026
$12.7B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding MDGL, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding MDGL at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Madrigal Pharmaceuticals, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)4:57 PM ETSep 9-112 daysSibold William JohnPresident and CEOSSale−11.6K$538.65−$6.24M−5.5%197.7K after24 lots10b5-1
Aug 20, 2026 (view filing)4:20 PM ETAug 173 daysLateKelley Shannon TGeneral CounselSSale−664$514.97−$341.9K−5.5%11.5K after
Jul 20, 2026 (view filing)9:16 PM ETJul 20Same daySibold William JohnPresident and CEOSSale−2.50K$547.30−$1.37M−1.2%209.3K after10 lots
Jun 1, 2026 (view filing)Jun 1Same daySoergel DavidChief Medical OfficerSSale−1.04K$495.74−$516.6K−9.4%10.0K after10b5-1
May 22, 2026 (view filing)May 22Same dayLevy Richard SDirectorSSale−5.68K$515.44−$2.93M−20.5%22.0K after12 lots10b5-1
May 18, 2026 (view filing)May 18Same daySoergel DavidChief Medical OfficerSSale−844$515.90−$435.4K−7.1%11.1K after
Mar 6, 2026 (view filing)Mar 6Same dayDier MardiEVP and CFOSSale−1.98K$430.87−$854.0K−13.7%12.5K after12 lots10b5-1
Mar 6, 2026 (view filing)Mar 6Same daySibold William JohnPresident and CEOSSale−1.66K$431.94−$718.3K−1.0%161.8K after
Mar 6, 2026 (view filing)Mar 6Same dayKelley Shannon TGeneral CounselSSale−360$431.94−$155.5K−2.9%12.1K after
Mar 6, 2026 (view filing)Mar 6Same dayHuntsman CaroleChief Commercial OfficerSSale−419$431.94−$181.0K−3.2%12.7K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Madrigal Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 414 holders
Institutions holding MDGL in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Baker Bros. Advisors LP2,143,131$1.15B5.77%+1,430+0.1%Added
RTW Investments, LP1,993,687$1.07B9.14%00.0%Unchanged
Jupiter Topco LLC1,936,099$1.04B0.42%+1,936,099New
Avoro Capital Advisors LLC1,833,333$984.4M8.84%+15,152+0.8%Added
Paulson & Co. Inc.1,340,020$719.5M27.94%−52,168−3.7%Reduced
BlackRock, Inc.1,200,770$644.8M0.01%−359,195−23.0%Reduced
Vanguard Capital Management LLC835,668$448.7M0.01%+8,524+1.0%Added
Wellington Management Group LLP825,714$443.4M0.08%+130,756+18.8%Added
Vanguard Portfolio Management LLC781,731$419.8M0.02%−59,414−7.1%Reduced
State Street Corp527,057$283.0M0.01%−82,468−13.5%Reduced

Holders of 5% or more of MDGL

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Madrigal Pharmaceuticals, Inc..

See all 1 holders and filings
Largest holders of MDGL from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Janus Henderson Group PLC13G/A10.10%2.21M shares–Feb 14, 20251 filingFeb 14, 2025SEC

Congress trades

1 member of Congress reported 1 trade in Madrigal Pharmaceuticals, Inc. since 2020. Newest filings:

All congress trades in MDGL
  1. Daniel S. Goldman

    Democrat · House · NY · May 19, 2023

    Sell$1K-$15K